News & Views
Agreement initiates development of therapy for neurodegenerative diseases
Oct 14 2015
Georg-August-University Göttingen (UMG) and UK medical research charity MRC Technology (MRCT), have signed an agreement for the development of a novel therapy for neurodegenerative diseases based on antibody targeting amyloid beta peptides 4-x. The aim is to develop a therapy for Alzheimer's Disease (AD).
The license, negotiated by MBM ScienceBridge GmbH, the technology transfer organisation of the Georg-August-Universität Göttingen, will enable UMG to access the antibody humanisation expertise of MRCT’s Centre for Therapeutics Discovery and the work of its Therapeutic Antibody Group, led by Dr. David Matthews.
MRCT will receives an exclusive worldwide license to the IP rights of UMG related to a novel therapeutic approach for the treatment of sporadic and familial AD, based on a panel of unique antibodies developed by its scientist Prof. Dr. Thomas Bayer. MRCT and UMG will then receive downstream payments dependent on the successful development and out-licensing of the antibody. This income will be used for further research within the organisations.
Digital Edition
Lab Asia 31.4 August 2024
August 2024
Chromatography Articles - HPLC gradient validation using non-invasive flowmeters Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers Labo...
View all digital editions
Events
Sep 11 2024 Bangkok, Thailand
Sep 11 2024 Bangkok, Thailand
Sep 11 2024 Singapore
Sep 18 2024 Lausanne, Switzerland
Sep 19 2024 Shanghai, China